Participants who took tirzepatide (Zepbound) dropped an average of 50 pounds over 72 weeks. Those who took semaglutide ...

Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.